BMS Inks $1.35B Deal for Innovative Alzheimer's Antibody Therapies Targeting PyroGlu-Aβ

On December 19, BioArctic announced that it had entered into a global exclusive license agreement with Bristol-Myers Squibb regarding the pyroglutamate-modified β-amyloid (PyroGlu-Aβ) antibody program, including antibodies BAN1503 and BAN2803. The BAN2803 antibody also incorporates BioArctic's BrainTransporter technology.^TMTechnology.BioArctic to Receive $100 Million Upfront Payment and Up to $1.25 Billion in Milestone PaymentsBioArctic is also entitled to receive tiered royalties from global product sales.

According to the agreement,Bristol-Myers Squibb will have full responsibility for the global development and subsequent commercialization of BAN1503 and BAN2803 and related products.BioArctic will receive an upfront payment of $100 million and up to $1.25 billion in development, regulatory, and commercial milestones, as well as tiered royalties on global product sales.RoyaltyFeeBioArctic will retain the option to co-commercialize these products in the Nordic region.

BioArctic's PyroGlu-Aβ Antibody Program consists of novel antibodies targeting specifically truncated PyroGlu-Aβ. The monomers of PyroGlu-Aβ are highly prone to aggregation, leading to the formation of harmful aggregates, which result in cognitive impairment and other symptoms associated with Alzheimer’s disease.

Because of the larger volume,Biologics such as antibodies and enzymes are severely restricted by the blood-brain barrier when being taken up by the brain. Active transport, one of the body's own delivery mechanisms, can cross the blood-brain barrier. Transferrin receptor (TfR) is a protein that facilitates transport across the blood-brain barrier, and BioArctic's BrainTransporter technology can utilize TfR to optimize drug delivery to the brain.

BioArctic retains all other rights to use the BrainTransporter platform. The BrainTransporter technology can be applied to biomolecular delivery across many different therapeutic areas, offering BioArctic numerous potential future collaboration opportunities.

Richard Hargreaves, Senior Vice President of Bristol-Myers Squibb and Head of the Neuroscience Research Center, stated: "Our agreement with BioArctic has the potential to further strengthen and diversify our growing neuroscience portfolio, reinforcing our commitment to exploring innovative and potentially transformative approaches to Alzheimer's disease, as there remains significant unmet need in the Alzheimer’s field."Clinical needs."We look forward to advancing and optimizing the development of anti-Aβ antibody therapy based on professional knowledge and utilizing cutting-edge innovative technologies, such as BioArctic's BrainTransporter technology."